1. Home
  2. ORGN vs CRDL Comparison

ORGN vs CRDL Comparison

Compare ORGN & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Materials Inc.

ORGN

Origin Materials Inc.

HOLD

Current Price

$2.45

Market Cap

12.4M

Sector

Industrials

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.31

Market Cap

154.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORGN
CRDL
Founded
2008
2017
Country
United States
Canada
Employees
91
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4M
154.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ORGN
CRDL
Price
$2.45
$1.31
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
90.7K
838.0K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$503.74
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.88
52 Week High
$4.11
$1.71

Technical Indicators

Market Signals
Indicator
ORGN
CRDL
Relative Strength Index (RSI) 58.29 47.38
Support Level $1.89 $0.95
Resistance Level $4.11 $1.43
Average True Range (ATR) 0.22 0.11
MACD -0.03 -0.03
Stochastic Oscillator 66.07 4.65

Price Performance

Historical Comparison
ORGN
CRDL

About ORGN Origin Materials Inc.

Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: